Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer

Annette R. Kodahl*, Sidse Ehmsen, Niels Pallisgaard, Anne M.B. Jylling, Jeanette D. Jensen, Anne Vibeke Lænkholm, Ann S. Knoop, Henrik J. Ditzel

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

123 Downloads (Pure)

Resumé

Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance, and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly sensitive, optimized droplet digital PCR (ddPCR) assay. We found 83% of patients with PIK3CA mutation in the metastatic tumor tissue also had detectable PIK3CA mutations in serum ctDNA. Patients lacking the PIK3CA mutation in corresponding serum ctDNA all had nonvisceral metastatic disease. Four patients with detectable PIK3CA-mutated ctDNA were followed with an additional serum sample during oncological treatment. In all cases, changes in PIK3CA ctDNA level correlated with treatment response. Our results showed high concordance between detection of PIK3CA mutations in tumor tissue and in corresponding serum ctDNA and suggest that serum samples from patients with advanced breast cancer and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as an early marker of treatment response.

OriginalsprogEngelsk
TidsskriftMolecular Oncology
Vol/bind12
Udgave nummer6
Sider (fra-til)925-935
ISSN1574-7891
DOI
StatusUdgivet - jun. 2018

Fingeraftryk

DNA
Mutation
Neoplasms
Serum
Circulating Neoplastic Cells
Polymerase Chain Reaction
Precision Medicine
Early Detection of Cancer
Paraffin
Formaldehyde

Bibliografisk note

© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Citer dette

Kodahl, Annette R. ; Ehmsen, Sidse ; Pallisgaard, Niels ; Jylling, Anne M.B. ; Jensen, Jeanette D. ; Lænkholm, Anne Vibeke ; Knoop, Ann S. ; Ditzel, Henrik J. / Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. I: Molecular Oncology. 2018 ; Bind 12, Nr. 6. s. 925-935.
@article{57f9a60f1b6f4b62a5d8acd97cf8de3f,
title = "Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer",
abstract = "Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance, and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly sensitive, optimized droplet digital PCR (ddPCR) assay. We found 83{\%} of patients with PIK3CA mutation in the metastatic tumor tissue also had detectable PIK3CA mutations in serum ctDNA. Patients lacking the PIK3CA mutation in corresponding serum ctDNA all had nonvisceral metastatic disease. Four patients with detectable PIK3CA-mutated ctDNA were followed with an additional serum sample during oncological treatment. In all cases, changes in PIK3CA ctDNA level correlated with treatment response. Our results showed high concordance between detection of PIK3CA mutations in tumor tissue and in corresponding serum ctDNA and suggest that serum samples from patients with advanced breast cancer and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as an early marker of treatment response.",
keywords = "ddPCR, liquid biopsy, metastatic breast cancer, PIK3CA",
author = "Kodahl, {Annette R.} and Sidse Ehmsen and Niels Pallisgaard and Jylling, {Anne M.B.} and Jensen, {Jeanette D.} and L{\ae}nkholm, {Anne Vibeke} and Knoop, {Ann S.} and Ditzel, {Henrik J.}",
note = "{\circledC} 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",
year = "2018",
month = "6",
doi = "10.1002/1878-0261.12305",
language = "English",
volume = "12",
pages = "925--935",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "6",

}

Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. / Kodahl, Annette R.; Ehmsen, Sidse; Pallisgaard, Niels; Jylling, Anne M.B.; Jensen, Jeanette D.; Lænkholm, Anne Vibeke; Knoop, Ann S.; Ditzel, Henrik J.

I: Molecular Oncology, Bind 12, Nr. 6, 06.2018, s. 925-935.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer

AU - Kodahl, Annette R.

AU - Ehmsen, Sidse

AU - Pallisgaard, Niels

AU - Jylling, Anne M.B.

AU - Jensen, Jeanette D.

AU - Lænkholm, Anne Vibeke

AU - Knoop, Ann S.

AU - Ditzel, Henrik J.

N1 - © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2018/6

Y1 - 2018/6

N2 - Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance, and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly sensitive, optimized droplet digital PCR (ddPCR) assay. We found 83% of patients with PIK3CA mutation in the metastatic tumor tissue also had detectable PIK3CA mutations in serum ctDNA. Patients lacking the PIK3CA mutation in corresponding serum ctDNA all had nonvisceral metastatic disease. Four patients with detectable PIK3CA-mutated ctDNA were followed with an additional serum sample during oncological treatment. In all cases, changes in PIK3CA ctDNA level correlated with treatment response. Our results showed high concordance between detection of PIK3CA mutations in tumor tissue and in corresponding serum ctDNA and suggest that serum samples from patients with advanced breast cancer and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as an early marker of treatment response.

AB - Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance, and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly sensitive, optimized droplet digital PCR (ddPCR) assay. We found 83% of patients with PIK3CA mutation in the metastatic tumor tissue also had detectable PIK3CA mutations in serum ctDNA. Patients lacking the PIK3CA mutation in corresponding serum ctDNA all had nonvisceral metastatic disease. Four patients with detectable PIK3CA-mutated ctDNA were followed with an additional serum sample during oncological treatment. In all cases, changes in PIK3CA ctDNA level correlated with treatment response. Our results showed high concordance between detection of PIK3CA mutations in tumor tissue and in corresponding serum ctDNA and suggest that serum samples from patients with advanced breast cancer and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as an early marker of treatment response.

KW - ddPCR

KW - liquid biopsy

KW - metastatic breast cancer

KW - PIK3CA

U2 - 10.1002/1878-0261.12305

DO - 10.1002/1878-0261.12305

M3 - Journal article

C2 - 29689598

AN - SCOPUS:85047898960

VL - 12

SP - 925

EP - 935

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 6

ER -